by Bonnell Foundation | Feb 13, 2018 | News
February 12, 2018 — Vertex announced that the U.S. FDA approved SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of...
